Professor David Taylor MSc PhD FRPharmS FRCPEdin FRCPsych(Hon)
Professor of Psychopharmacology
Research interests
- Pharmacology
Contact details
Biography
David Taylor is Director of Pharmacy and Pathology at the Maudsley Hospital and Professor of Psychopharmacology at KCL. In 2014, David was ranked in the top 100 clinical leaders in the NHS by the Health Service Journal. David is the Editor-in-Chief of the journal Therapeutic Advances in Psychopharmacology (IF 5.0). David was a member of the UK Department of Transport expert panel that introduced drug-driving regulation. He is currently a member of the UK government’s Advisory Council on Misuse of Drugs. He has formally contributed to five NICE Guidelines. Professor Taylor has been the lead author of the Maudsley Prescribing Guidelines since their inception in 1993. The Maudsley Prescribing Guidelines have sold over 300,000 copies in fourteen editions and twelve languages. David has also authored over 375 clinical papers in journals such as the Lancet, BMJ, JAMA Psychiatry, British Journal of Psychiatry and Journal of Clinical Psychiatry. These papers have been cited over 14,000 times. Professor Taylor has an H Index of 69.
Research
Medicines Use
The Medicines Use Research Group provides expertise on the evaluation, optimisation and risk associated with medicines.
TIES Project
Telephone delivered Incentives for Encouraging adherence to Supervised methadone consumption:development and feasibility study clinical and cost effectiveness.
Project status: Ongoing
STOP-D (Sertraline TO prevent Post-TBI Depression)
A multi-centre placebo-controlled double blind RCT to investigate the use of sertraline in reducing depressive symptoms in traumatic brain injury patients.
Project status: Ongoing
Research
Medicines Use
The Medicines Use Research Group provides expertise on the evaluation, optimisation and risk associated with medicines.
TIES Project
Telephone delivered Incentives for Encouraging adherence to Supervised methadone consumption:development and feasibility study clinical and cost effectiveness.
Project status: Ongoing
STOP-D (Sertraline TO prevent Post-TBI Depression)
A multi-centre placebo-controlled double blind RCT to investigate the use of sertraline in reducing depressive symptoms in traumatic brain injury patients.
Project status: Ongoing